New shot in the arm: testing a Next-Generation pneumonia vaccine
NCT ID NCT07428759
Summary
This study is testing a new version of a pneumonia vaccine called PnMAPS30plus in healthy adults aged 50 to 64. About 120 participants will receive one dose of either the new vaccine or an already approved one and be followed for about six months. The main goals are to check if the new vaccine is safe and if it helps the body build protective antibodies against pneumococcal bacteria, which can cause serious infections like pneumonia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA, BACTERIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
Norwood, South Australia, 5067, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.